Opus Point Partners Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Opus Point Partners Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-35,000	Closed	-$4.19M	–	63
2017 Q4	$4.19M	Hold	35,000	–	–	3.62%	9
2017 Q3	$4.91M	Hold	35,000	–	–	4.41%	6
2017 Q2	$4.26M	Hold	35,000	–	–	3.9%	6
2017 Q1	$4.24M	Buy	+35,000	New	+$4.51M	3.15%	10
2015 Q1	–	Sell	-100	Closed	-$355K	–	72
2014 Q4	$355K	Buy	+100	New	+$18.5K	0.35%	52

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Opus Point Partners Management's ALXN Position: Q3 2019 in Review

Opus Point Partners Management increased its Alexion Pharmaceuticals (ALXN) stake by 0.06% in Q3 2019, buying an estimated $676 and bringing the position to 9,933 shares worth $973K. The position accounts for 1.76% of the portfolio, ranked #11.

Opus Point Partners Management first reported a position in ALXN in Q4 2014 and has held it in 20 quarters since. The position peaked at $6.29M in Q4 2015. 647 funds tracked by Wall St. Rank hold ALXN as of Q3 2019.

Opus Point Partners Management held 9,933 shares of Alexion Pharmaceuticals worth $973K as of Q3 2019.
Opus Point Partners Management bought 6 Alexion Pharmaceuticals shares in Q3 2019, an estimated $676.
Alexion Pharmaceuticals made up 1.76% of Opus Point Partners Management's portfolio in Q3 2019, its #11 holding.
Opus Point Partners Management first reported a position in Alexion Pharmaceuticals in Q4 2014 and has held it in 20 quarters since.
Opus Point Partners Management's Alexion Pharmaceuticals position peaked at $6.29M in Q4 2015.
647 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2019.

Based on Opus Point Partners Management's 13F filing for Q3 2019, filed 14 Nov 2019.